Cell therapy specialist SQZ Biotechnologies has expanded a collaboration with Swiss giant Roche (ROG: SIX) to bring forward candidates based on antigen presenting cells (APCs).
APCs are involved in activating T cell responses and play a critical role in certain responses against viruses and tumors.
The deal, which builds on a major collaboration agreement the firms reached in 2015, seeks to combine SQZ’s cell therapy know-how with Roche’s immunotherapy expertise.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze